28 November 2019 - Health care funders have been urged to overcome the “scary” cost of emerging gene therapies that have the potential to cure — rather than just treat — a range of difficult diseases.

Gene — or gene-modified cell — therapy has become a hot area of medical research, but with it comes the multi-billion-dollar price tag of drugs that, to date, have tackled a small patient base of rare (orphan) diseases.

But with “extraordinary” clinical results emerging, pressure is mounting on governments and private funders to subsidise the cost of such treatments which can cost millions of dollars over a patient’s lifespan.

Read The Australian article